125 related articles for article (PubMed ID: 37933074)
21. Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens.
Luo W; Yu H; Zou X; Ni X; Wei J
Cancer Biomark; 2018; 23(4):485-494. PubMed ID: 30347595
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
23. Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.
Palmieri R; Buckley SA; Othus M; Halpern AB; Percival MM; Scott BL; Hendrie PC; Becker PS; Oehler VG; Estey EH; Walter RB
Leuk Lymphoma; 2020 Jul; 61(7):1728-1731. PubMed ID: 32077361
[No Abstract] [Full Text] [Related]
24. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.
Mirza AS; Lancet JE; Sweet K; Padron E; Pinilla-Ibarz J; Nardelli L; Cubitt C; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):902-907. PubMed ID: 29030092
[TBL] [Abstract][Full Text] [Related]
25. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.
Wang L; Luo J; Chen G; Fang M; Wei X; Li Y; Liu Z; Zhang Y; Gao S; Shen J; Wang X; Gao X; Zhou W; Ma Y; Liu H; Li X; Yang L; Sun K; Yu L
Clin Epigenetics; 2020 Sep; 12(1):132. PubMed ID: 32873343
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after 'CLAG-M' vs. 'MEC'.
Scheckel CJ; Meyer M; Betcher JA; Al-Kali A; Foran J; Palmer J
Leuk Res; 2020 Mar; 90():106300. PubMed ID: 32018118
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of cladribine addition to induction treatment of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis.
Pan Q; Li J
Hematology; 2021 Dec; 26(1):577-587. PubMed ID: 34384339
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia.
Yao H; Zhang C; Tan X; Li J; Yin X; Deng X; Chen T; Rao J; Gao L; Kong P; Zhang X
Cancer Med; 2023 Jun; 12(11):12377-12387. PubMed ID: 37161845
[TBL] [Abstract][Full Text] [Related]
29. Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Walti CS; Halpern AB; Xie H; Kiem ES; Chung EL; Schonhoff KG; Huebner EM; Delaney C; Liu C; Pergam SA; Cheng GS; Kimball LE; Leisenring WM; Boeckh M; Walter RB; Hill JA
Leukemia; 2023 Feb; 37(2):298-307. PubMed ID: 36509892
[TBL] [Abstract][Full Text] [Related]
30. Salvaging AML with CLAG: novel option, or more of the same?
Wei A; Teh TC
Leuk Res; 2011 Mar; 35(3):297-8. PubMed ID: 21074270
[No Abstract] [Full Text] [Related]
31. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
[TBL] [Abstract][Full Text] [Related]
32. Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.
Halpern AB; Rodríguez-Arbolí E; Othus M; Garcia KA; Percival MM; Cassaday RD; Oehler VG; Becker PS; Appelbaum JS; Abkowitz JL; Orozco JJ; Keel SB; Hendrie PC; Scott BL; Ghiuzeli MC; Estey EH; Walter RB
Blood Adv; 2023 Sep; 7(17):4950-4961. PubMed ID: 37339483
[TBL] [Abstract][Full Text] [Related]
33. Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia.
Patzke CL; Duffy AP; Duong VH; El Chaer F; Trovato JA; Baer MR; Bentzen SM; Emadi A
J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32079074
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.
Ramsingh G; Westervelt P; McBride A; Stockerl-Goldstein K; Vij R; Fiala M; Uy G; Cashen A; Dipersio JF; Abboud CN
Int J Hematol; 2014 Mar; 99(3):272-8. PubMed ID: 24488798
[TBL] [Abstract][Full Text] [Related]
35. Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia.
Liu L; Zhang Y; Jin Z; Zhang X; Zhao G; Si Y; Lin G; Ma A; Sun Y; Wang L; Wu D
Int J Hematol; 2014; 99(5):603-8. PubMed ID: 24623261
[TBL] [Abstract][Full Text] [Related]
36. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
Jaglal MV; Duong VH; Bello CM; Al Ali NH; Padron E; Fernandez HF; List AF; Lancet JE; Komrokji RS
Leuk Res; 2014 Apr; 38(4):443-6. PubMed ID: 24439565
[TBL] [Abstract][Full Text] [Related]
37. Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.
Ye P; Pei R; Jin J; Sun J; Li K; Cao J; Zhou D; Lu Y
Ann Hematol; 2019 Sep; 98(9):2073-2080. PubMed ID: 31201514
[TBL] [Abstract][Full Text] [Related]
38. Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
Schoen MW; Woelich SK; Braun JT; Reddy DV; Fesler MJ; Petruska PJ; Freter CE; Lionberger JM
Leuk Res; 2018 May; 68():72-78. PubMed ID: 29574395
[TBL] [Abstract][Full Text] [Related]
39. Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia.
Abboud R; Chendamarai E; Rettig MP; Trinkaus KM; Riedell PA; Abboud CN; Ghobadi A; Pusic I; Stockerl-Goldstein K; Schroeder MA; Vij R; Westervelt P; DiPersio JF; Uy GL
Haematologica; 2020 Aug; 105(8):e404-e407. PubMed ID: 31753931
[No Abstract] [Full Text] [Related]
40. [Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene].
Li XL; Liu LP; Wan Y; Liu F; Chen X; Ren YY; Ruan M; Guo Y; Zhu XF; Yang WY
Zhonghua Er Ke Za Zhi; 2023 Apr; 61(4):357-362. PubMed ID: 37011983
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
